Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Recent long-term data on pembrolizumab and nivolumab has reaffirmed the benefits of anti-PD-1 therapies in managing residual melanoma. However, Funck-Brentano cautioned, “Most patients do not ...

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...